Pfizer’s world headquarters in New York City, US. Credit: Norbert Nagel, Mörfelden-Walldorf, Germany.

Biotechnology company Allogene Therapeutics has signed an asset contribution deal with Pfizer over allogeneic chimeric antigen receptor T cell (CAR T) therapy assets being developed to treat cancer.

Under the partnership, Pfizer will own a 25% stake in Allogene and will offer financial support to develop the CAR T portfolio, which includes 16 preclinical assets and UCART19.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Allogene intends to assume the global strategic collaboration agreement originally formed with Cellectis in 2014 for the development of ‘off-the-shelf’ CAR T immunotherapies from Pfizer.

Pfizer will continue to hold 8% shares in Cellectis.

“The portfolio of CAR T assets contributed by Pfizer will be well-positioned to rapidly advance into potential innovative new therapies, and ultimately to reach patients in need more quickly.”

Pfizer oncology research & development senior vice-president and group head Robert Abraham said: “We believe that under the strong scientific, clinical development and regulatory expertise of Allogene’s leadership team, the portfolio of CAR T assets contributed by Pfizer will be well-positioned to rapidly advance into potential innovative new therapies, and ultimately to reach patients in need more quickly.”

The deal will provide Allogene with exclusive rights for the development and commercialisation of pre-defined allogeneic UCART programmes intended for specific targets.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Cellectis will receive up to $2.8bn based on clinical and commercial milestones, or $185m for each of the 15 targets and tiered royalties on net sales of any associated products commercialised by Allogene.

Allogene president and CEO David Chang said: “Our mission at Allogene is to catalyse the next revolution in cancer treatment through the development of allogeneic CAR T therapies directed at blood cancers as well as solid tumours.

“We believe this collaboration fuels our mission and we look forward to partnering with Cellectis to accelerate the development of allogeneic cell therapies.”

Subject to closing conditions, the asset contribution agreement is scheduled to be completed in the second quarter of this year.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platform is transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.

Discover the Impact